Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the...
FOR IMMEDIATE RELEASE Every patient deserves a treatment they know will work for them.” ~ Reg Seeto, CEO, Scipher Medicine BURLINGTON, MA, UNITED STATES /EINPresswire.com/ — Scipher Medicine, a leader in precision medicine for autoimmune diseases, today...
FOR IMMEDIATE RELEASE Scipher Medicine and Senelix Announce Strategic Collaboration to Advance SL300 Development Baltimore, MD, March 10th, 2026 — Scipher Medicine and Senelix today announced a strategic collaboration to incorporate Scipher’s AI network platform to...
Drug discovery and development remains one of the most challenging and resource-intensive processes in modern medicine. With development timelines spanning 10-15 years and costs exceeding $1-3 billion per approved drug1, the need for more efficient target...
